GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00988768 | Prostate | BPH | vesicle-mediated transport to the plasma membrane | 43/3107 | 136/18723 | 1.11e-05 | 1.51e-04 | 43 |
GO:001943910 | Prostate | BPH | aromatic compound catabolic process | 113/3107 | 467/18723 | 1.30e-05 | 1.72e-04 | 113 |
GO:006100816 | Prostate | BPH | hepaticobiliary system development | 46/3107 | 150/18723 | 1.36e-05 | 1.78e-04 | 46 |
GO:00714787 | Prostate | BPH | cellular response to radiation | 54/3107 | 186/18723 | 1.50e-05 | 1.92e-04 | 54 |
GO:190136110 | Prostate | BPH | organic cyclic compound catabolic process | 118/3107 | 495/18723 | 1.75e-05 | 2.17e-04 | 118 |
GO:000188916 | Prostate | BPH | liver development | 45/3107 | 147/18723 | 1.76e-05 | 2.18e-04 | 45 |
GO:00430879 | Prostate | BPH | regulation of GTPase activity | 88/3107 | 348/18723 | 2.04e-05 | 2.49e-04 | 88 |
GO:005134616 | Prostate | BPH | negative regulation of hydrolase activity | 94/3107 | 379/18723 | 2.46e-05 | 2.94e-04 | 94 |
GO:00365034 | Prostate | BPH | ERAD pathway | 35/3107 | 107/18723 | 3.17e-05 | 3.60e-04 | 35 |
GO:00516488 | Prostate | BPH | vesicle localization | 51/3107 | 177/18723 | 3.20e-05 | 3.61e-04 | 51 |
GO:006021310 | Prostate | BPH | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 9/3107 | 13/18723 | 3.55e-05 | 3.90e-04 | 9 |
GO:00610148 | Prostate | BPH | positive regulation of mRNA catabolic process | 30/3107 | 87/18723 | 3.72e-05 | 4.04e-04 | 30 |
GO:00066134 | Prostate | BPH | cotranslational protein targeting to membrane | 15/3107 | 31/18723 | 4.00e-05 | 4.30e-04 | 15 |
GO:00068928 | Prostate | BPH | post-Golgi vesicle-mediated transport | 34/3107 | 104/18723 | 4.14e-05 | 4.43e-04 | 34 |
GO:00611578 | Prostate | BPH | mRNA destabilization | 29/3107 | 84/18723 | 4.86e-05 | 5.07e-04 | 29 |
GO:00304333 | Prostate | BPH | ubiquitin-dependent ERAD pathway | 29/3107 | 85/18723 | 6.22e-05 | 6.23e-04 | 29 |
GO:001095115 | Prostate | BPH | negative regulation of endopeptidase activity | 66/3107 | 252/18723 | 6.87e-05 | 6.78e-04 | 66 |
GO:001046616 | Prostate | BPH | negative regulation of peptidase activity | 68/3107 | 262/18723 | 7.28e-05 | 7.13e-04 | 68 |
GO:00002898 | Prostate | BPH | nuclear-transcribed mRNA poly(A) tail shortening | 14/3107 | 29/18723 | 7.48e-05 | 7.24e-04 | 14 |
GO:00720016 | Prostate | BPH | renal system development | 76/3107 | 302/18723 | 8.55e-05 | 8.09e-04 | 76 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C6 | SNV | Missense_Mutation | | c.201N>C | p.Lys67Asn | p.K67N | P13671 | protein_coding | tolerated(0.09) | possibly_damaging(0.717) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
C6 | SNV | Missense_Mutation | | c.1672G>A | p.Asp558Asn | p.D558N | P13671 | protein_coding | tolerated(0.09) | benign(0.29) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
C6 | SNV | Missense_Mutation | | c.1375N>G | p.Lys459Glu | p.K459E | P13671 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs369381506 | c.1067N>A | p.Arg356Gln | p.R356Q | P13671 | protein_coding | tolerated(0.17) | benign(0.098) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs763860114 | c.2522G>A | p.Arg841His | p.R841H | P13671 | protein_coding | tolerated(0.19) | benign(0.35) | TCGA-C8-A12Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | | c.311N>T | p.Arg104Ile | p.R104I | P13671 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
C6 | SNV | Missense_Mutation | novel | c.1177N>A | p.Glu393Lys | p.E393K | P13671 | protein_coding | tolerated(0.24) | benign(0.169) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828_829insG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | deletion | Frame_Shift_Del | rs372345940 | c.828delN | p.Ser277AlafsTer43 | p.S277Afs*43 | P13671 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828dupG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |